GW
Gregory W. Matz
Senior Vice President, Finance & Accounting, Principal Financial & Accounting Officer
Dare BioscienceTherapeutic Areas
Dare Bioscience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DARE-LARC1 | Year-long, user-controlled reversible contraception | Phase 1 |
| DARE-BV1 | Treatment of Bacterial Vaginosis (BV) | Phase 3 |
| Ovaprene | Non-hormonal, monthly intravaginal contraceptive | Phase 3 |
| DARE-HRT1 | Localized hormone therapy for Genitourinary Syndrome of Menopause (GSM) | Preclinical |
| Sildenafil Cream, 3.6% | Treatment of Female Sexual Arousal Disorder (FSAD) | Phase 2b |
Leadership Team at Dare Bioscience
SM
Sabrina Martucci Johnson
President, Chief Executive Officer & Director
JA
John A. Fair
Chief Strategy Officer, Head of Corporate Development & Investor Relations
CR
Cheryl R. Blanchard
Chief Scientific Officer
LW
Lisa Walters-Hoffert
Chief Financial Officer
DR
David R. Friend
Chief Development Officer
JG
Joseph G. (Joe) Cook, Jr.
Chairman of the Board
DB
David B. Friend
Director
RL
Robin L. Steele
Director
RD
Roger D. Dansey
Director